OBJECTIVES: To estimate the rates of cardiovascular events (CVE) among elderly high cardiovascular risk patients METHODS: The Truven Health MarketScan Medicare Supplemental Database was used to hierarchically identify cohorts of elderly adults (age 65-75) with familial hypercholesteremia (FH), atherosclerotic cardiovascular disease (ASCVD) [myocardial infarction; unstable angina; ischemic stroke; stable angina; coronary revascularization; carotid stenosis; peripheral vascular disease; abdominal aortic aneurysm] or type 2 diabetes mellitus (T2DM) in 2006-2007; a variable-length follow-up was used to describe lipid-lowering therapy (LLT) and  rates of new CVE from 2008-2013.  The ASCVD and T2DM cohorts included patients prescribed statin at and ≤12 months post diagnosis; FH cohort included patients prescribed high intensity statin and ezetimibe concurrently for ≥30 days at and <12 month post diagnosis. The primary outcome was the presence of new CVEs, defined as an inpatient stay with a primary diagnosis of acute coronary syndrome ([ACS] includes myocardial infarction and unstable angina), ischemic stroke, heart failure, revascularization or cardiovascular-related death. RESULTS: